New drug cocktail aims to shrink ovarian tumors before surgery
NCT ID NCT07407452
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial will test a combination of the experimental drug QL1706 with standard chemotherapy or with olaparib and intraperitoneal chemotherapy as a pre-surgery treatment for 50 women with advanced ovarian cancer. The goal is to see if this approach can shrink tumors enough to make surgery more effective. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iparomlimab and tuvonralimab (QL1706) combined with chemotherapy drugs (paclitaxel, carboplatin, cisplatin) or olaparib
What this could lead to
If successful, this could lead to a new treatment option before surgery for advanced ovarian cancer, potentially improving tumor shrinkage and surgical outcomes.
What could go wrong
This is an early Phase 2 trial with only 50 patients, so results may not apply to everyone. The combination of multiple drugs may cause significant side effects, and it is not yet known if it will improve long-term survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••